Hoersholm, Denmark, August 24, 2018 – Medical Prognosis Institute A/S (now Oncology Venture A/S) (the “Company“) and Oncology Venture Sweden AB (“OV“) hereby announce, as part of the completion of the previously announced merger between the two companies, that the merger has been registered with the Danish Business Authority and that the Danish Business Authority has notified the Swedish Companies Registration Office (Sw. Bolagsverket) that the legal effects of the merger have commenced. As part of the registration of the merger, the share capital in the Company has been increased to nominal DKK 2,513,563.90 as further described in the merger prospectus issued on May 1, 2018.
OV has applied for de-listing from Spotlight Stock Market (previously AktieTorget) and the last day of trading in OV shares will be August 31, 2018. After the OV shares have been de-listed from Spotlight Stock Market and the Swedish Companies Registration Office has de-registered OV from the Swedish Companies Register (Sw. Aktiebolagsregistret), those who are shareholders in OV as of September 7, 2018 (the record date for the merger) will receive 1.8524 new ordinary shares in the Company for each share held in OV. Distribution of the new ordinary shares that have been issued in the Company as merger consideration is expected to take place on September 11, 2018. Cash payments following the sale of fractional shares by Sedermera Fondkommission, as further described in the merger plan and the merger prospectus, are expected to be distributed to the entitled recipients on or around September 12, 2018. The shareholders do not have to take any actions in relation to the foregoing.
The Company has changed name from Medical Prognosis Institute A/S to Oncology Venture A/S in connection with the registration of the merger as further described in the merger prospectus. The Company will continue to be listed on Nasdaq First North and will as of September 3, 2018 be traded under the name “Oncology Venture A/S”.
For further information, please contact:
CEO, Peter Buhl Jensen, MD, PhD Ulla Hald Buhl, IR & Communication
E-mail: pbj@medical-prognosis.com E-mail: uhb@medical-prognosis.com
Telephone: +45 21 60 89 22 Telephone +45 21 70 10 49
This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on August 24, 2018.
Certified Adviser: Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden
About MPI
Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP® technology. MPI’s exceptional opportunity to personalize cancer treatment – begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI’s DRP® tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,100 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.
On the May 30, 2018, MPI and Oncology Ventures respective general assemblies decided to merge. Last day of trading in the Oncology Venture share is August 31, 2018.
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of MPI’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning MPI’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. MPI undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Attachment
